The invention relates to fusions of coagulation Factor IX (FIX) and transferrin (Tf). These FIX-Tf fusion proteins can be administered orally, and are capable of reaching the systemic circulation by utilizing an endocytosis-dependent mechanism to cross the gut epithelium. Upon delivery of FIX-Tf fusion proteins to the systemic circulation, the fusion proteins are useful for treating bleeding disorders, such as haemophilia B.

Disclosed herein are antimicrobial constructs comprising a membrane interacting peptide and an antimicrobial agent. Also disclosed are methods for making and using the constructs.

Disclosed herein are antimicrobial constructs comprising a membrane interacting peptide and an antimicrobial agent. Also disclosed are methods for making and using the constructs.

Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

There is provided a means for sterilizing lactoferrin at a high temperature in a short time while maintaining the activity of the lactoferrin. The present technology provides a method for producing a lactoferrin-containing aqueous solution, including a sterilization step of heat-sterilizing a lactoferrin-containing aqueous solution, in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, at a temperature of 100° C. or more. The present technology also provides a lactoferrin-containing aqueous solution in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, and which does not contain living bacteria.

The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.